BioTuesdays

Category - Markets

Apollo Endosurgery
Markets

Piper starts Apollo Endosurgery at overweight; PT $8

Piper Jaffray launched coverage of Apollo Endosurgery (NASDAQ:LAPEN) with an “overweight” rating and $8 price target. The stock closed at $5.85 on April 12. Apollo is focused on bariatric and general surgery procedures...

April 13, 2018
Aptevo Therapeutics
Markets

Roth start Aptevo at buy; PT $12

Roth Capital Partners initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and price target of $12. The stock closed at $3.28 on April 11. “In our view, Aptevo remains under the Street’s...

April 12, 2018
vTv Therapeutics Logo
Markets

Stifel cuts vTv Therapeutics to hold; PT to $1 from $12

Stifel downgraded vTv Therapeutics (NASDAQ:VTVT) to “hold” from “buy” and slashed its price target to $1 from $12 after the company reported negative top line results from its Phase 3 STEADFAST study in mild Alzheimer’s...

April 10, 2018
Exact Sciences Logo
Markets

BTIG ups Exact Sciences to buy; PT $60

BTIG upgraded Exact Sciences (NASDAQ:EXAS) to “buy” from “neutral” with a price target of $60, citing an approximate 35% drop in the stock price since November, which it said offers an “attractive entry point.” The...

April 3, 2018
Allena Pharmaceuticals Logo
Markets

Roth starts Allena Pharma at buy; PT $61

Roth Capital Partners initiated coverage of Allena Pharmaceuticals (NASDAQ: ALNA) with a “buy” rating and a $61 price target. The stock closed at $11.02 on March 29. Allena is focused on the treatment of enteric...

April 2, 2018
Flex Pharma
Markets

Ladenburg ups Flex Pharma PT to $20 from $13

Ladenburg Thalmann raised its price target for Flex Pharma (NASDAQ:FLKS) to $20 from $13 after the company announced that its lead asset, FLX-787, reduced the frequency of cramps/spasms in a 57-patient, placebo...

March 29, 2018
Revance
Markets

Needham starts Revance Therapeutics at buy; PT $42

Needham initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $42 price target. The stock closed at $30.60 on March 26. Revance is involved in the development of novel and differentiated...

March 27, 2018